share_log
Reuters ·  01/07 06:02

Avenzo Therapeutics: Dualitybio to Be Eligible to Receive up to About $1.15 Bln in Development, Regulatory & Commercial Milestone Payments

Avenzo Therapeutics:Dualitybio有资格获得高达约11.5亿美元的开发、监管和商业里程碑付款

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发